Japanese Encephalitis

Phase 3Biologic

Novartis

Japanese Encephalitis is one of 20 biologic programs targeting Japanese encephalitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Japanese EncephalitisActive, not recruiting

Japanese EncephalitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Japanese Encephalitis

#DrugCompanyPhaseTrials

Hepatitis a Vaccine

Sanofi

Phase 3

1 2

Prevnar

GSK

Phase 3

1 3

Havrix

GSK

Phase 3

1 4

Measles Vaccine

GSK

Phase 3

1 5

Rituxan

Roche

Phase 2

—6

Measles-Mumps-Rubella Vaccine

LLiaoning Chengda Biotechnology CO., LTD

Approved

2 7

Virazole

CConrado Roberto Hoffmann Filho

Phase 2

1 8

Varicella Vaccine

Sanofi

Phase 3

1 9

Immunoglobulin

Sanofi

Phase 2

1 10

Rabies

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]